https://www.ajmc.com/view/trilaciclib-may-reduce-hospitalization-and-improve-survival-in-es-sclc
Patients with extensive-stage small cell lung cancer (ES-SCLC) who receive trilaciclib appear to experience lower rates of hematologic adverse effects than...
trilaciclibmayreducehospitalizationimprove